Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Media Fact Sheet Novartis in Ophthalmology The medical retina pipeline includes investigational treatments in late-stage clinical development, for both dry and wet AMD Novartis is dedicated to the research, development and manufacturing of ophthalmic pharmaceuticals Novartis’ commitment in ophthalmology Novartis is dedicated to the research, development and manufacturing of ophthalmic pharmaceuticals and devices. The mission of Novartis in the field of ophthalmology is to discover, develop and manufacture innovative products to improve eye health and enhance people’s lives. Novartis businesses specifically dedicated to eye health include Alcon, the leading eye care business in the world and the company’s second largest growth platform behind Pharmaceuticals. Part of Alcon is CIBA Vision, which is committed to the research, development and manufacturing of optical and ophthalmic products and services. Both Novartis Pharma Ophthalmics and Alcon/Ciba Vision, address unmet medical needs of patients in a complementary fashion to treat eye diseases, vision conditions and common refractory errors. Lucentis In 2006 Novartis launched Lucentis® (ranibizumab), a humanized therapeutic antibody fragment, for the treatment of ocular conditions. Lucentis is approved in more than 100 countries for the treatment of patients with wet age-related macular degeneration (wet AMD), for the treatment of visual impairment due to diabetic macular edema (DME) and for the treatment of macular edema secondary to retinal vein occlusion (RVO). Lucentis is approved in more than 60 countries to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). In most European countries Lucentis is administered for the treatment of wet AMD, DME, RVO and myopic CNV to patients on an individualized basis with the goal of maximizing visual outcomes for each individual patient whilst minimizing the risks of over- or under-treating. LUMINOUS™ Heritage The Novartis Pharma division partnered with QLT Inc (transferred to Valeant Pharmaceuticals International Inc in September 2012) to launch the first therapeutic treatment approved worldwide for the treatment of certain forms of wet AMD, Visudyne® (verteporfin) PDT. Today, Novartis Pharma markets and develops Lucentis, the first anti-VEGF approved for four different indications. Founded in 1945, Alcon has grown from a small ophthalmic shop, to a global business with a focus on surgical, pharmaceutical and vision care products. In March 2012, Alcon announced that it had gained exclusive rights to commercialize Jetrea® (ocriplasmin) outside the United States for the treatment of vitreomacular traction (VMT). Jetrea was approved by the European Commission on 15 March 2013 and is becoming available across Europe for the treatment of vitreomacular traction (VMT), including when associated with macular hole, in adults. Novartis has launched LUMINOUS™, one of the largest global observational studies in ophthalmology to date, aiming to advance the understanding of retinal vascular diseases that cause vision loss and to evaluate the long-term effectiveness and safety profile of Lucentis in routine clinical practice across large populations. The program is designed to allow patients, physicians and other healthcare professionals to record and monitor visual acuity and other patient-reported outcomes. In addition, the program will act as a robust post-market surveillance tool. Currently, more than 20,000 patients are enrolled in this study. XOVA Novartis and Alcon sponsor the “eXcellence in Ophthalmology Vision Award” (XOVA). XOVA is an annual award launched in 2010 that provides funding to support innovative, sustainable projects to non-profit initiatives that aim to reduce the burden of blindness. There have been 11 awards to date and the scope of projects from the 2012 applications included: improving eye care in children, reaching rural communities, providing training and education, building or expanding eye-care centers, and installing or improving technology. Novartis Pharma AG CH-4002 Basel, Switzerland © 2014 Novartis Pharma AG